Home › Type 1 Diabetes › NCT07803744

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

A Phase 1, Investigator- and Participant- Blinded, Randomized, Placebo-Controlled, Single-Dose Study to Investigate the Impact of Tirzepatide on Gastric Emptying in Adult Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

Who can join

Ages 18 to 70 · All sexes

Inclusion Criteria:

* Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening
* Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg/m2) at screening
* Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening

Exclusion Criteria:

* Participants who have a known clinically significant gastric emptying abnormality
* Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery
* Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists

About the study

The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.

Participation in this study will last about 8 weeks, including screening and follow-up.

What is being tested

• Tirzepatide (drug)
• Acetaminophen (drug)
• Placebo (drug)

Sponsor: Eli Lilly and Company · Participants: 18 · Started: Sep 11, 2026

Contact the study team

• Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · Phone: 1-317-615-4559

Official record on ClinicalTrials.gov — NCT07803744

Locations in the U.S.

Conditions

• Type 1 Diabetes
• Overweight
• Obesity

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.